Published in J Drugs Dermatol on February 08, 2005
Therapeutic effect of sodium selenite and zinc sulphate as supplementary with meglumine antimoniate( glucantime®) against cutaneous leishmaniasis in BALB/c mice. Iran J Parasitol (2010) 0.83
Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis. Indian J Dermatol (2012) 0.80
Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials. PLoS One (2015) 0.78
Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial. PLoS One (2013) 0.76
Anti Leishmanial Effect of Zinc Sulphate on the Viability of Leishmania tropica and L. major Promastigotes. Jundishapur J Microbiol (2014) 0.76
Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions. Antimicrob Agents Chemother (2015) 0.75
Effect of trinitroglycerin therapy on serum zinc and copper levels and liver enzyme activities in BALB/c mice infected with Leishmania major MRHO/IR/75/ER. Iran J Basic Med Sci (2015) 0.75
Comparison between intralesional injection of zinc sulfate 2 % solution and intralesional meglumine antimoniate in the treatment of acute old world dry type cutaneous leishmaniasis: a randomized double-blind clinical trial. J Parasit Dis (2014) 0.75
Comparative genomic and phylogeographic analysis of Mycobacterium leprae. Nat Genet (2009) 2.76
Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med (2006) 2.60
First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine (2008) 1.71
Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine (2007) 1.66
Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine (2009) 1.59
Opium and risk of laryngeal cancer. Laryngoscope (2003) 1.42
Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine (2005) 1.30
Emergence of a new focus of anthroponotic cutaneous leishmaniasis due to Leishmania tropica in rural communities of Bam district after the earthquake, Iran. Trop Med Int Health (2011) 1.28
Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol (2007) 1.27
Leishmania species: detection and identification by nested PCR assay from skin samples of rodent reservoirs. Exp Parasitol (2010) 1.25
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19
Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol (2006) 1.18
Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother (2009) 1.15
CD8+ T cells as a source of IFN-γ production in human cutaneous leishmaniasis. PLoS Negl Trop Dis (2010) 1.14
Pigmented Bowen's disease of the finger mimicking malignant melanoma. Arch Iran Med (2007) 1.13
Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach. Exp Parasitol (2013) 1.10
Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatr Nephrol (2007) 1.10
Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994-2006. Int J Dermatol (2010) 1.06
Laser hair removal: comparison of long-pulsed Nd:YAG, long-pulsed alexandrite, and long-pulsed diode lasers. Dermatol Surg (2004) 1.06
Giant bilateral becker nevus: a rare presentation. Pediatr Dermatol (2008) 1.03
Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine (2006) 1.03
Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol (2005) 1.03
Stem cell therapy in treatment of different diseases. Acta Med Iran (2012) 1.02
Variation of biophysical parameters of the skin with age, gender, and body region. ScientificWorldJournal (2012) 1.00
The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate. Parasitol Res (2011) 0.96
What patients with vitiligo believe about their condition. Int J Dermatol (2004) 0.95
Bony lesions in pediatric acute leukemia: pictorial essay. Iran J Radiol (2012) 0.93
Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Exp Parasitol (2006) 0.90
The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis. Am J Pathol (2005) 0.89
Enhancement of peritoneal macrophage phagocytic activity against Leishmania major by garlic (Allium sativum) treatment. J Ethnopharmacol (2005) 0.89
Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis. Eur J Dermatol (2007) 0.89
Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol (2006) 0.88
Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN. Parasitol Res (2010) 0.88
Increased phosphorylation of mTOR is involved in remote ischemic preconditioning of hippocampus in mice. Brain Res (2013) 0.88
Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous leishmaniasis. J Infect (2007) 0.88
Long-term skin damage due to chemical weapon exposure. Cutan Ocul Toxicol (2010) 0.87
Concepts of patients with alopecia areata about their disease. BMC Dermatol (2005) 0.86
Overexpression of ubiquitin and amino acid permease genes in association with antimony resistance in Leishmania tropica field isolates. Korean J Parasitol (2013) 0.86
Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin Vaccine Immunol (2008) 0.86
Effect of crocus sativus on gentamicin induced nephrotoxicity. Biol Res (2010) 0.86
Morphine dependence protects rat kidney against ischaemia-reperfusion injury. Clin Exp Pharmacol Physiol (2008) 0.86
Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. Vaccine (2012) 0.86
Oral and jaw lymphoma in an Iranian population. J Craniofac Surg (2011) 0.86
Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis. Vaccine (2012) 0.85
Template protocol for clinical trials investigating vaccines--focus on safety elements. Vaccine (2013) 0.84
Surrogate markers of immunity to Leishmania major in leishmanin skin test negative individuals from an endemic area re-visited. Vaccine (2006) 0.84
Nitric oxide and renal protection in morphine-dependent rats. Free Radic Biol Med (2010) 0.84
Assessment of histologic criteria in the diagnosis of mycosis fungoides. Int J Dermatol (2003) 0.84
First molecular identification of Leishmania species in a new endemic area of cutaneous leishmaniasis in Lorestan, Iran. Asian Pac J Trop Med (2013) 0.84
Macular amyloidosis: an assessment of prevalence, sex, and age. Int J Dermatol (2004) 0.83
Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice. Acta Trop (2012) 0.83
Regulatory T-cell profile in early and late lesions of cutaneous leishmaniasis due to Leishmania major. J Res Med Sci (2012) 0.83
CCR7+ central and CCR7- effector memory CD4+ T cells in human cutaneous leishmaniasis. J Clin Immunol (2012) 0.82
Exposure to Leishmania major modulates the proportion of CD4+ T cells without affecting cellular immune responses. Microbiol Immunol (2007) 0.81
Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice. Iran J Basic Med Sci (2013) 0.81
The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63). Exp Parasitol (2009) 0.81
Acne and smoking: is there a relationship? BMC Dermatol (2005) 0.81
Effect of DHA+EPA on oxidative stress and apoptosis induced by ischemia-reperfusion in rat kidneys. Fundam Clin Pharmacol (2012) 0.81
BCL-2 and Bax Expression in Skin Flaps Treated with Finasteride or Azelaic Acid. Iran J Pharm Res (2012) 0.81
Pimecrolimus cream in repigmentation of vitiligo. Dermatology (2007) 0.80
The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. Exp Parasitol (2012) 0.80
Expression of Bcl-2 and Bax after hippocampal ischemia in DHA + EPA treated rats. Neurol Sci (2011) 0.80
Salivary levels of secretary IgA, C5a and alpha 1-antitrypsin in sulfur mustard exposed patients 20 years after the exposure, Sardasht-Iran Cohort Study (SICS). Int Immunopharmacol (2013) 0.80
Unwanted facial hair removal with laser treatment improves quality of life of patients. J Cosmet Laser Ther (2010) 0.79
Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis. Parasitol Res (2012) 0.79
Introducing new vaccines in developing countries. Expert Rev Vaccines (2013) 0.79
Effect of short and long-term treatment with omega-3 Fatty acids on scopolamine-induced amnesia. Iran J Pharm Res (2012) 0.79
Systematic review of New World cutaneous leishmaniasis: several points. Int J Dermatol (2009) 0.79
Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition. Colloids Surf B Biointerfaces (2009) 0.79
The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine (2002) 0.78
Few comments on the treatment of Old World cutaneous leishmaniasis. Int J Dermatol (2011) 0.78
CD30+ Large Cell Transformation of Mycosis Fungoides During Pregnancy. Indian J Dermatol (2013) 0.78
Comparison of long-pulsed alexandrite and Nd:YAG lasers, individually and in combination, for leg hair reduction: an assessor-blinded, randomized trial with 18 months of follow-up. Arch Dermatol (2008) 0.78
Cryotherapy for anogenital warts: factors affecting therapeutic response. Dermatol Online J (2007) 0.78
Antioxidants and proinflamatory cytokines in the sera of patients with cutaneous leishmaniasis. Iran J Immunol (2012) 0.78
The changing profile of cutaneous leishmaniasis agent in a central province of Iran. Tanzan J Health Res (2013) 0.77
Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model. Iran J Basic Med Sci (2012) 0.77
Itraconazole in the treatment of cutaneous leishmaniasis. Int J Dermatol (2006) 0.77
Skeletal muscle post-conditioning by diazoxide, anti-oxidative and anti-apoptotic mechanisms. Mol Biol Rep (2012) 0.77
Safety reporting in developing country vaccine clinical trials-a systematic review. Vaccine (2012) 0.77
Cutaneous leishmaniasis. Lancet Infect Dis (2008) 0.77
Comparison of intradermal injection with iontophoresis of abobotulinum toxin A for the treatment of primary axillary hyperhidrosis: a randomized, controlled trial. J Dermatolog Treat (2013) 0.77